TCRX Fundamental Analysis - TSCAN THERAPEUTICS INC

Name: TSCAN THERAPEUTICS INC (TCRX) Stock
Brand: TSCAN THERAPEUTICS INC
Rating: 3.5 (3 reviews)

Fundamental Rating

Overall TCRX gets a fundamental rating of 2 out of 10. We evaluated TCRX against 534 industry peers in the Biotechnology industry. TCRX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. TCRX is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year TCRX has reported negative net income.

TCRX had a negative operating cash flow in the past year.

TCRX had negative earnings in each of the past 5 years.

TCRX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -45.81%, TCRX perfoms like the industry average, outperforming 54.31% of the companies in the same industry.

TCRX's Return On Equity of -77.40% is in line compared to the rest of the industry. TCRX outperforms 53.93% of its industry peers.

		Industry Rank	Sector Rank
ROA	-45.81%
ROE	-77.4%
ROIC	N/A

ROA(3y)-33.47%

ROA(5y)-35.77%

ROE(3y)-59.56%

ROE(5y)-72.17%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TCRX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

TCRX does not have a ROIC to compare to the WACC, probably because it is not profitable.

TCRX has more shares outstanding than it did 1 year ago.

TCRX has more shares outstanding than it did 5 years ago.

The debt/assets ratio for TCRX has been reduced compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -2.59, we must say that TCRX is in the distress zone and has some risk of bankruptcy.

With a Altman-Z score value of -2.59, TCRX perfoms like the industry average, outperforming 48.13% of the companies in the same industry.

A Debt/Equity ratio of 0.18 indicates that TCRX is not too dependend on debt financing.

TCRX's Debt to Equity ratio of 0.18 is on the low side compared to the rest of the industry. TCRX is outperformed by 67.60% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.18
Debt/FCF	N/A
Altman-Z	-2.59

ROIC/WACCN/A

WACC9.33%

2.3 Liquidity

TCRX has a Current Ratio of 7.06. This indicates that TCRX is financially healthy and has no problem in meeting its short term obligations.

Looking at the Current ratio, with a value of 7.06, TCRX is in the better half of the industry, outperforming 70.04% of the companies in the same industry.

TCRX has a Quick Ratio of 7.06. This indicates that TCRX is financially healthy and has no problem in meeting its short term obligations.

TCRX's Quick ratio of 7.06 is fine compared to the rest of the industry. TCRX outperforms 70.41% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	7.06
Quick Ratio	7.06

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for TCRX have decreased by -3.81% in the last year.

Looking at the last year, TCRX shows a very negative growth in Revenue. The Revenue has decreased by -42.96% in the last year.

The Revenue for TCRX have been decreasing by -34.76% on average. This is quite bad

EPS 1Y (TTM)-3.81%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%0%

Revenue 1Y (TTM)-42.96%

Revenue growth 3Y-34.76%

Revenue growth 5YN/A

Sales Q2Q%473.88%

3.2 Future

TCRX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.00% yearly.

TCRX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 100.43% yearly.

EPS Next Y-0.78%

EPS Next 2Y-3.16%

EPS Next 3Y7.61%

EPS Next 5Y7%

Revenue Next Year182.46%

Revenue Next 2Y55.73%

Revenue Next 3Y153.6%

Revenue Next 5Y100.43%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

TCRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year TCRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-3.16%

EPS Next 3Y7.61%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for TCRX!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

TSCAN THERAPEUTICS INC

NASDAQ:TCRX (11/4/2025, 8:00:00 PM)

Premarket: 1.11 -0.01 (-0.89%)

1.12

-0.12 (-9.68%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)08-12 2025-08-12/bmo

Earnings (Next)11-05 2025-11-05/bmo

Inst Owners79.48%

Inst Owner Change-0.61%

Ins Owners0.26%

Ins Owner Change0%

Market Cap63.56M

Revenue(TTM)6.96M

Net Income(TTM)-136775000

Analysts84.29

Price Target8.67 (674.11%)

Short Float %3.21%

Short Ratio3.79

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)6.52%

Min EPS beat(2)2.17%

Max EPS beat(2)10.87%

EPS beat(4)3

Avg EPS beat(4)5.1%

Min EPS beat(4)-7.46%

Max EPS beat(4)14.81%

EPS beat(8)6

Avg EPS beat(8)9.75%

EPS beat(12)8

Avg EPS beat(12)7.49%

EPS beat(16)11

Avg EPS beat(16)8.95%

Revenue beat(2)2

Avg Revenue beat(2)103.65%

Min Revenue beat(2)92.64%

Max Revenue beat(2)114.66%

Revenue beat(4)2

Avg Revenue beat(4)38.13%

Min Revenue beat(4)-51.71%

Max Revenue beat(4)114.66%

Revenue beat(8)3

Avg Revenue beat(8)11.64%

Revenue beat(12)4

Avg Revenue beat(12)7.48%

Revenue beat(16)6

Avg Revenue beat(16)7.6%

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)-5.04%

EPS NY rev (1m)0%

EPS NY rev (3m)-1.41%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)31.6%

Revenue NY rev (1m)0%

Revenue NY rev (3m)37.03%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	9.13
P/FCF	N/A
P/OCF	N/A
P/B	0.36
P/tB	0.36
EV/EBITDA	N/A

EPS(TTM)-1.09

EYN/A

EPS(NY)-1.22

Fwd EYN/A

FCF(TTM)-2.31

FCFYN/A

OCF(TTM)-2.22

OCFYN/A

SpS0.12

BVpS3.11

TBVpS3.11

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-45.81%
ROE	-77.4%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-33.47%

ROA(5y)-35.77%

ROE(3y)-59.56%

ROE(5y)-72.17%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score1

Asset Turnover0.02

Health

		Industry Rank	Sector Rank
Debt/Equity	0.18
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	162.78%
Cap/Sales	72.82%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	7.06
Quick Ratio	7.06
Altman-Z	-2.59

F-Score1

WACC9.33%

ROIC/WACCN/A

Cap/Depr(3y)78.03%

Cap/Depr(5y)175.46%

Cap/Sales(3y)60.67%

Cap/Sales(5y)133.81%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-3.81%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%0%

EPS Next Y-0.78%

EPS Next 2Y-3.16%

EPS Next 3Y7.61%

EPS Next 5Y7%

Revenue 1Y (TTM)-42.96%

Revenue growth 3Y-34.76%

Revenue growth 5YN/A

Sales Q2Q%473.88%

Revenue Next Year182.46%

Revenue Next 2Y55.73%

Revenue Next 3Y153.6%

Revenue Next 5Y100.43%

EBIT growth 1Y-29.25%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-5.53%

EBIT Next 3Y19.08%

EBIT Next 5YN/A

FCF growth 1Y-60.67%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-60.5%

OCF growth 3YN/A

OCF growth 5YN/A

TSCAN THERAPEUTICS INC / TCRX FAQ

What is the ChartMill fundamental rating of TSCAN THERAPEUTICS INC (TCRX) stock?

ChartMill assigns a fundamental rating of 2 / 10 to TCRX.

What is the valuation status for TCRX stock?

ChartMill assigns a valuation rating of 0 / 10 to TSCAN THERAPEUTICS INC (TCRX). This can be considered as Overvalued.

How profitable is TSCAN THERAPEUTICS INC (TCRX) stock?

TSCAN THERAPEUTICS INC (TCRX) has a profitability rating of 1 / 10.

Can you provide the expected EPS growth for TCRX stock?

The Earnings per Share (EPS) of TSCAN THERAPEUTICS INC (TCRX) is expected to decline by -0.78% in the next year.

TSCAN THERAPEUTICS INC (TCRX) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

TSCAN THERAPEUTICS INC / TCRX FAQ

What is the ChartMill fundamental rating of TSCAN THERAPEUTICS INC (TCRX) stock?

What is the valuation status for TCRX stock?

How profitable is TSCAN THERAPEUTICS INC (TCRX) stock?

Can you provide the expected EPS growth for TCRX stock?